Johnson & Johnson (NYSE:JNJ) Price Target Raised to $285.00 at Citigroup

Johnson & Johnson (NYSE:JNJ) had its price target raised by Citigroup from $274.00 to $285.00 in a research report sent to investors on Tuesday morning,MarketScreener reports. Citigroup currently has a buy rating on the stock.

Several other research analysts have also recently commented on the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. TD Cowen raised their target price on shares of Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Scotiabank reiterated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Bank of America reiterated a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 2nd. Finally, Barclays increased their price target on shares of Johnson & Johnson from $217.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 19th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $237.57.

Johnson & Johnson Stock Down 1.0%

Shares of JNJ opened at $238.47 on Tuesday. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $251.71. The firm’s 50 day moving average is $240.53 and its 200-day moving average is $214.17. The stock has a market capitalization of $574.38 billion, a PE ratio of 21.58, a P/E/G ratio of 2.41 and a beta of 0.34. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion for the quarter. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by company insiders.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock worth $49,740,362,000 after purchasing an additional 3,731,074 shares during the period. State Street Corp lifted its holdings in shares of Johnson & Johnson by 1.3% during the fourth quarter. State Street Corp now owns 133,869,843 shares of the company’s stock worth $27,704,364,000 after purchasing an additional 1,663,782 shares during the period. Auto Owners Insurance Co lifted its holdings in shares of Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock worth $11,967,947,000 after purchasing an additional 1,738,292 shares during the period. Finally, Norges Bank acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $6,924,523,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Citigroup raised its price target to $285 and kept a “buy” rating, implying roughly 20% upside from recent levels — a notable analyst vote of confidence for JNJ’s outlook. Read More.
• Positive Sentiment: Guggenheim also nudged up its target to $244 and maintained a “buy” rating, adding incremental analyst support for the stock. Read More.
• Positive Sentiment: JNJ received CE‑Mark clearance and launched the next‑gen VARIPULSE Pro PFA catheter in Europe — a commercial milestone that should support MedTech sales growth in international markets. Read More.
• Positive Sentiment: Specialty therapy updates: JNJ secured a permanent US reimbursement code for bladder cancer drug INLEXZO, reported 52‑week efficacy for ICOTYDE in psoriasis, and struck an exclusive Japan distribution deal for SIRTURO (drug‑resistant TB). These moves improve commercial visibility and address previous undervaluation arguments. Read More.
• Neutral Sentiment: Technical / timing note: Dow Jones/Investors.com flagged JNJ as in or near a buy zone — bullish from a trading setup perspective but not a fundamental catalyst. Read More.
• Neutral Sentiment: Analyst consensus remains around “Moderate Buy,” reflecting broad analyst support but not unanimous enthusiasm; watch for further analyst commentary and earnings updates. Read More.
• Neutral Sentiment: Longer‑term comparison pieces (e.g., JNJ vs KO) highlight JNJ’s dividend durability and oncology growth but don’t present immediate price catalysts. Read More.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.